POHL DAVID 4
4 · PEREGRINE PHARMACEUTICALS INC · Filed Aug 29, 2017
Insider Transaction Report
Form 4
POHL DAVID
Director
Transactions
- Other
Stock Option (right to buy)
2017-08-25−11,908→ 262,305 totalExercise: $9.17Exp: 2025-05-11→ Common Stock (11,908 underlying)
Footnotes (2)
- [F1]Pursuant to the settlement terms of a derivative lawsuit approved by Vice Chancellor Laster by Order dated July 27, 2017 (the "Settlement Date"), Mr. Pohl has agreed to an annual compensation cap for a period of two years from the Settlement Date. Although not required, on August 25, 2017, Mr. Pohl voluntarily surrendered for cancelation and for no consideration, 11,908 options (originally granted on May 11, 2015), which reduced his total annual compensation for fiscal year 2016 to below the agreed upon cap.
- [F2]The underlying option grant provided for vesting in eight (8) equal quarterly installments over a two (2) year period beginning August 11, 2015 and each quarter thereafter until fully-vested.